New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Inzaugarat, María Eugenia ^a   De Matteo, Elena ^b   Baz, Placida ^a   Lucero, Diego ^a   García, Cecilia Claudia ^a   Ballerga, Esteban Gonzalez ^c   Daruich, Jorge ^c   Sorda, Juan Antonio ^c   Wald, Miriam Ruth ^d   Cherñavsky, Alejandra Claudia ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^d PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CURCUMIN; GAMMA INTERFERON; GLUCOSE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; ANTIOXIDANT; LEPTIN; LINOLEIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FATTY LIVER; LIPID DIET; LIVER; LIVER CELL; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CD4-POSITIVE T-LYMPHOCYTES; CURCUMIN; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATOCYTES; HUMANS; LEPTIN; LINOLEIC ACID; LIVER; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; REACTIVE OXYGEN SPECIES;

EID: 85014312731     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172900     Document Type: Article

References (34)

1. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annual review of pathology. 2010; 5:145-71. doi: 10.1146/annurev-pathol-121808-102132 PMID: 20078219
2. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology (Baltimore, Md). 2010; 52(5):1836-46.
3. Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Frontiers in immunology. 2014; 5:177. doi: 10.3389/fimmu.2014.00177 PMID: 24795720
4. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World journal of gastroenterology: WJG. 2012; 18(8):727-35. doi: 10.3748/wjg.v18.i8.727 PMID: 22371632
5. Vonghia L, Michielsen P, Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. International journal of molecular sciences. 2013; 14(10):19867-90. doi: 10.3390/ijms141019867 PMID: 24084730
6. + effector T cell responses. Journal of immunology (Baltimore, Md: 1950). 2012; 189(6):2941-53.
7. - conventional T cells. Metabolism: clinical and experimental. 2014; 63 (10):1272-9.
8. Lam QL, Lu L. Role of leptin in immunity. Cellular & molecular immunology. 2007; 4(1):1-13.
9. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. Journal of immunology (Baltimore, Md: 1950). 2005; 174(6):3137-42.
10. Procaccini C, Pucino V, Mantzoros CS, Matarese G. Leptin in autoimmune diseases. Metabolism: clinical and experimental. 2015; 64(1):92-104.
11. Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism: clinical and experimental. 2015; 64(1):60-78.
12. Chatterjee S, Ganini D, Tokar EJ, Kumar A, Das S, Corbett J, et al. Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis. J Hepatol. 2013; 58(4):778-84. doi: 10.1016/j.jhep.2012.11.035 PMID: 23207144
13. Sutti S, Jindal A, Locatelli I, Vacchiano M, Gigliotti L, Bozzola C, et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology (Baltimore, Md). 2014; 59(3):886-97.
14. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003; 52(12):2882-7. PMID: 14633847
15. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 2009; 50(6): 1827-38. doi: 10.1002/hep.23229 PMID: 19937697
16. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007; 46(4): 1081-90. doi: 10.1002/hep.21763 PMID: 17654743
17. Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010; 51(10): 3046-54. doi: 10.1194/jlr.M007096 PMID: 20631297
18. Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang Ret al. Oxnash score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci. 2014; 59(7): 1617-24. doi: 10.1007/s10620-014-3031-8 PMID: 24464211
19. Shishodia S. Molecular mechanisms of curcumin action: Gene expression. BioFactors. 2013; 39(1):37-55. doi: 10.1002/biof.1041 PMID: 22996381
20. Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014; 25(1): 1-18. doi: 10.1016/j.jnutbio.2013.09.001 PMID: 24314860
21. Shapiro H, Bruck R. Therapeutic potential of curcumin in non-alcoholic steatohepatitis. Nutrition Research Reviews. 2005; 18(02): 212-21.
22. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res. 1999; 39(1): 41-7. doi: 10.1006/phrs.1998.0404 PMID: 10051376
23. Kim G, Jang MS, Son YM, Seo MJ, Ji SY, Han SH et al. Curcumin inhibits cd4(+) t cell activation, but augments cd69 expression and tgf-beta1-mediated generation of regulatory t cells at late phase. PLOSone. 2013; 8(4): e62300
24. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012; 32(1): 3-13. doi: 10.1055/s-0032-1306421 PMID: 22418883
25. Sellmayer A, Obermeier H, Danesch U, Aepfelbacher M, Weber PC. Arachidonic acid increases activation of nadph oxidase in monocytic u937 cells by accelerated translocation of p47-phox and co-stimulation of protein kinase c. Cell Signal. 1996; 8(5): 397-402. PMID: 8911691
26. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: Mechanisms of action. Clin Exp Immunol. 2003; 133(1): 11-9. doi: 10.1046/j.1365-2249.2003.02190.x PMID: 12823272
27. Lazarevic V, Glimcher LH. T-bet in disease. Nat Immunol. 2011; 12(7): 597-606. doi: 10.1038/ni.2059 PMID: 21685955
28. Oner-Iyidogan Y, Tanrikulu-Kucuk S, Seyithanoglu M, Koçak H, Doǧru-Abbasoǧlu S, Aydin AF et al. Effect of curcumin on hepatic heme oxygenase 1 expression in high fat diet fed rats: Is there a triangular relationship? Can J Physiol Pharmacol. 2014; 92(10): 805-12. doi: 10.1139/cjpp-2014-0174 PMID: 25211173
29. Balteau M, Tajeddine N, de Meester C, Ferté L, Battault S, Ravenstein CMet al. Nadph oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires sglt1. Cardiovasc Res. 2011; 92(2): 237-46. doi: 10.1093/cvr/cvr230 PMID: 21859816
30. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. Journal of Hepatology. 51(1): 212-23. doi: 10.1016/j.jhep.2009.03.008 PMID: 19447517
31. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr. 2010; 30: 173-99. doi: 10.1146/annurev.nutr.012809.104755 PMID: 20420526
32. Farrell GC, Mridha AR, Yeh MM, Arsov T, Van Rooyen DM, Brooling J et al. Strain dependence of dietinduced nash and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. Liver Int. 2014; 34(7): 1084-93. doi: 10.1111/liv.12335 PMID: 24107103
33. Huang XD, Fan Y, Zhang H, Maachi M, Wendum D, Paye F et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol. 2008; 14(18): 2888-93. doi: 10.3748/wjg.14.2888 PMID: 18473416
34. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002; 21(3): 219-23. PMID: 12127930